Experimental and Clinical Research Center, Charité - Universitätsmedizin Berlin, Berlin, Germany.
Robert Koch Institute, Berlin, Germany.
Methods Mol Biol. 2022;2521:129-154. doi: 10.1007/978-1-0716-2441-8_7.
Genetic vaccination using naked plasmid DNA is an immunization strategy both against infectious diseases and cancer.In order to improve efficacy of DNA vaccines, particularly in large animals and humans, different strategies have been pursued. These vaccination strategies are based on different application routes, schedules and coexpression of immunomodulatory molecules as adjuvants. Our mouse tumor model offers the possibility to investigate Her2/neu DNA vaccines in different settings, that is, intramuscular or intradermal application with or without coexpression of adjuvants. The immunogenicity of predicted peptides for Her2/neu specific memory T cells were screened and confirmed after intramuscular and intradermal application. Protection from tumor growth in tumor challenge experiments and both T cell and humoral immune responses against Her2/neu peptides are used as surrogate parameters for vaccine efficacy.
使用裸露质粒 DNA 的基因疫苗接种是一种针对传染病和癌症的免疫策略。为了提高 DNA 疫苗的效力,特别是在大型动物和人类中,已经采用了不同的策略。这些疫苗接种策略基于不同的应用途径、方案和共表达免疫调节分子作为佐剂。我们的小鼠肿瘤模型为研究 Her2/neu DNA 疫苗在不同环境下的应用提供了可能性,即肌肉内或皮内应用,或与佐剂共表达。在肌肉内和皮内应用后,筛选并证实了预测的 Her2/neu 特异性记忆 T 细胞肽的免疫原性。在肿瘤攻击实验中,肿瘤生长的保护以及针对 Her2/neu 肽的 T 细胞和体液免疫反应被用作疫苗效力的替代参数。